Key Takeaways
- • Toscafund Asset Management, led by activist investor Martin Hughes ("the Rottweiler"), has proposed a £1 billion takeover of Spire Healthcare at 250p per share, backed unanimously by the board pending a firm offer.
- • Spire Healthcare's share price surged 47p to 221p (a 27% jump) on the takeover announcement, valuing the company at £892 million, after hitting a five-year low of 142p in March 2026.
- • Spire operates 38 private hospitals and over 60 clinics across England, Wales, and Scotland, serving 1.36 million patients in 2025, with approximately one-third of revenues derived from NHS work.
- • The bid followed collapsed merger talks with private equity firms Bridgepoint and Triton, after Triton withdrew in March 2026; Spire initiated a strategic review in September 2025.
- • Mediclinic Group currently holds a 29.9% minority stake in Spire Healthcare, which may factor into final deal structuring and approval.
Summary
Toscafund Asset Management has tabled a non-binding £1 billion acquisition proposal for Spire Healthcare, Britain's largest private hospital operator, at 250p per share. The proposal, led by Martin Hughes—a prominent City activist investor known for his aggressive takeover tactics and nicknamed "the Rottweiler"—received unanimous board backing, contingent on the submission of a formal offer. The deal structure represents a significant premium to Spire's depressed valuation, which had fallen to a five-year low of 142p in March 2026.
Market reaction was immediate and substantial. Spire's share price jumped 47p to 221p on announcement, representing a 27% single-day gain and valuing the company at £892 million at that level. This dramatic move reflects investor appetite for a resolution following months of strategic uncertainty. The healthcare operator operates an extensive network of 38 private hospitals and more than 60 clinics across England, Wales, and Scotland, delivering care to 1.36 million patients in 2025. The company was originally founded in 2007 through Bupa hospital acquisitions and rebrandings, subsequently floated in 2014, and has grown through strategic acquisitions and two new hospital builds in Manchester and Nottingham.
The Toscafund approach culminates a lengthy M&A process for Spire. The company initiated a strategic review in September 2025, subsequently entering advanced negotiations with private equity firms Bridgepoint and Triton. Those talks terminated in March 2026 when Triton withdrew from consideration, prompting the board to explore alternative bidders. Toscafund's emergence as a lead buyer represents a shift toward activist hedge fund ownership within UK private healthcare consolidation.
Structurally, Spire derives approximately one-third of its revenues from NHS contract work, primarily elective procedures including hip and knee operations. This NHS exposure will likely feature prominently in regulatory review and due diligence, as healthcare sector consolidation continues under increased regulatory scrutiny. Mediclinic Group's existing 29.9% minority stake in Spire Healthcare will also influence deal mechanics and shareholder approval dynamics. The proposed transaction reflects broader consolidation trends in UK private hospital operators, following comparable sector transactions.
Market reaction was immediate and substantial. Spire's share price jumped 47p to 221p on announcement, representing a 27% single-day gain and valuing the company at £892 million at that level. This dramatic move reflects investor appetite for a resolution following months of strategic uncertainty. The healthcare operator operates an extensive network of 38 private hospitals and more than 60 clinics across England, Wales, and Scotland, delivering care to 1.36 million patients in 2025. The company was originally founded in 2007 through Bupa hospital acquisitions and rebrandings, subsequently floated in 2014, and has grown through strategic acquisitions and two new hospital builds in Manchester and Nottingham.
The Toscafund approach culminates a lengthy M&A process for Spire. The company initiated a strategic review in September 2025, subsequently entering advanced negotiations with private equity firms Bridgepoint and Triton. Those talks terminated in March 2026 when Triton withdrew from consideration, prompting the board to explore alternative bidders. Toscafund's emergence as a lead buyer represents a shift toward activist hedge fund ownership within UK private healthcare consolidation.
Structurally, Spire derives approximately one-third of its revenues from NHS contract work, primarily elective procedures including hip and knee operations. This NHS exposure will likely feature prominently in regulatory review and due diligence, as healthcare sector consolidation continues under increased regulatory scrutiny. Mediclinic Group's existing 29.9% minority stake in Spire Healthcare will also influence deal mechanics and shareholder approval dynamics. The proposed transaction reflects broader consolidation trends in UK private hospital operators, following comparable sector transactions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.